Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.41 |
| ▸ | CNR1 | P21554 | 5/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670838 | 1.00 | CRHR1 (0.41) | CRHR1CNR1CNR2MAPK1SLC6A4 | |
| SCHEMBL13616695 | 0.89 | CRHR1 (0.50) | CRHR1CNR1CNR2MAPK1SLC6A4 | |
| SCHEMBL3841630 | 0.87 | CRHR1 (0.43) | CRHR1CNR1CNR2MAPK1SLC6A4 | |
| SCHEMBL3838890 | 0.87 | CRHR1 (0.43) | CRHR1 | |
| SCHEMBL13616936 | 0.84 | AURKA (0.41) | CRHR1CNR1CNR2MAPK1AURKA | |
| SCHEMBL3845218 | 0.80 | MAPK1 (0.42) | CRHR1CNR1CNR2MAPK1SLC6A4 | |
| SCHEMBL6646501 | 0.79 | CNR1 (0.42) | CRHR1CNR1CNR2MAPK1SMO | |
| SCHEMBL3839744 | 0.79 | CNR1 (0.42) | CRHR1CNR1CNR2MAPK1SLC6A3 | |
| SCHEMBL3838891 | 0.77 | CRHR1 (0.47) | CRHR1CNR1CNR2MAPK1SLC6A4 | |
| SCHEMBL3843277 | 0.77 | CRHR1 (0.47) | CRHR1CNR1CNR2MAPK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446387-B1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | CRHR1 27/4885CNR1 66/4885CNR2 72/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | CRHR1 27/4885CNR1 66/4885CNR2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.